PositoAI/ US/ CEL-SCI Corporation

CEL-SCI Corporation

NYSE American: CVM · Healthcare

Positivity Index

#2,659 / 6,774

Global

#913 / 4,000

United States

Positivity Score

21,273

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

CEL-SCI Corporation — Overview & Financial Snapshot

CEL-SCI Corporation (NYSE American: CVM) is a Healthcare company, ranked #2,659 of 6,774 companies globally and #913 of 4,000 in United States on PositoAI, with a Positivity Score of 21,273. Its market capitalisation is ₹267.30 Cr ($28.32M), P/E ratio is -1.0 and P/B ratio is 2.58. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

P/B Ratio 2.58

P/E Ratio -1.0

D/E Ratio 0.72

ROE -252.53%

Owes vs Owns ? 0.49× Low $0.49 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-159.52$-1.69

Forward EPS ₹-602.21$-6.38

Beta 0.59

Market Cap ₹267.30 Cr$28.32M

What these numbers mean →

What does CEL-SCI Corporation do?

What is CEL-SCI Corporation's P/E and P/B ratio?

CEL-SCI Corporation has a P/E ratio of -1.0 and a P/B ratio of 2.58.

What is CEL-SCI Corporation's debt-to-equity ratio?

CEL-SCI Corporation has a debt-to-equity ratio of 0.72.

How much does CEL-SCI Corporation owe compared with what it owns?

CEL-SCI Corporation owes $0.49 for every $1 it owns (balance sheet Jun 2026), which is low.

What is CEL-SCI Corporation's Positivity rank?

CEL-SCI Corporation is ranked #2,659 of 6,774 companies globally and #913 of 4,000 in United States on PositoAI, with a Positivity Score of 21,273.

Does CEL-SCI Corporation have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for CEL-SCI Corporation.

Where can I read the latest news about CEL-SCI Corporation?

Recent headlines about CEL-SCI Corporation from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does CEL-SCI Corporation have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of CEL-SCI Corporation's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.